Associated Papers
Nucleation and dissolution mechanism underlying amyotrophic lateral sclerosis/frontotemporal lobar dementia-linked fused in sarcoma condensates.
Djaja NA et al.
Iscience, 2023
Mechanism of karyopherin-β2 binding and nuclear import of ALS variants FUS(P525L) and FUS(R495X).
Gonzalez A et al.
Scientific Reports, 2021
Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation.
Naumann M et al.
Nature Communications, 2018
A novel mutation of the C-terminal amino acid of FUS (Y526C) strengthens FUS gene as the most frequent genetic factor in aggressive juvenile ALS.
Corcia P et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 2017
Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.
Troakes C et al.
Neuropathology and Applied Neurobiology, 2013
Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
Neumann M et al.
Acta Neuropathologica, 2012
Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS).
Zhang ZC et al.
Proceedings of the National Academy of Sciences of the United States of America, 2012
FUS-related proteinopathies: lessons from animal models.
Lanson NA et al.
Brain Research, 2012
FUS-NLS/Transportin 1 complex structure provides insights into the nuclear targeting mechanism of FUS and the implications in ALS.
Niu C et al.
Plos One, 2012
Select a paper to view details